Vis enkel innførsel

dc.contributor.authorJensvoll, Hilde
dc.contributor.authorBlix, Kristine
dc.contributor.authorBrækkan, Sigrid Kufaas
dc.contributor.authorHansen, John-Bjarne
dc.date.accessioned2014-12-22T08:14:02Z
dc.date.available2014-12-22T08:14:02Z
dc.date.issued2014-03-18
dc.description.abstractBackground: Elevated platelet count is associated with risk of venous thromboembolism in cancer patients initiating chemotherapy. It is not known whether this risk by platelet count is causal or merely reflects the malignant disease. We investigated whether pre-cancer platelet count alone or together with high leukocyte count was associated with risk of venous thromboembolism in subjects who did and did not develop cancer during follow-up in a population-based cohort study.<br> Methods: Platelet count and other baseline characteristics were measured in 25160 initially cancer-free subjects who participated in the Tromsø Study in 1994–1995. Incident cancer and symptomatic venous thromboembolism events were registered up to December 31st, 2009. Multivariable Cox regression models were used to calculate hazard ratio for venous thromboembolism across categories of platelet count (,40th, 40–80th, and .80th percentile) with 95% confidence interval.<br> Results: During follow-up, 2082 subjects were diagnosed with cancer. Platelet count was measured on average 8.3 years before the cancer diagnosis. There were 129 venous thromboembolism events in the cancer cohort (13.5 per 1000 personyears) and 377 in the non-cancer cohort (1.2 per 1000 person-years). In cancer patients, pre-cancer platelet count above the 80th percentile ($2956109/L) was associated with a 2-fold higher risk of venous thromboembolism (Hazard ratio: 1.98, 95% confidence interval 1.21–3.23) compared to platelet count below the 40th percentile (,2356109/L). Concomitant high platelet and leukocyte counts showed a synergistic effect on the VTE risk. In cancer-free subjects, no association was found.<br> Comment: In conclusion, pre-cancer platelet count was associated with risk of symptomatic venous thromboembolism in cancer patients, but not in cancer-free subjects. Our findings suggest that platelet count and platelet-leukocyte interactions may play a role in the pathogenesis of cancer-related venous thromboembolism.en
dc.identifier.citationPLoS ONE, 2014, 9 (3), e92011.en
dc.identifier.issn1932-6203
dc.identifier.otherFRIDAID 1161581
dc.identifier.other10.1371/journal.pone.0092011
dc.identifier.urihttp://hdl.handle.net/10037/6959
dc.identifier.urnURN:NBN:no-uit_munin_6560
dc.language.isoengen
dc.publisherPublic Library of Science (PLoS)en
dc.rights.accessRightsopenAccess
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Hematologi: 775en
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762en
dc.titlePlatelet Count Measured Prior to Cancer Development Is a Risk Factor for Future Symptomatic Venous Thromboembolism: The Tromsø Studyen
dc.typeJournal articleen
dc.typeTidsskriftartikkelen
dc.typePeer revieweden


Tilhørende fil(er)

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel